Home›The Library›Pegfilgrastim
Pegfilgrastim
Pegfilgrastim (Neulasta) is a real, FDA-approved PEGylated version of filgrastim, engineered so its own clearance mechanism is regulated by the neutrophil count it's meant to raise — allowing one dose per chemotherapy cycle instead of daily injections.
In brief
Should you care? Relevant if you or someone you know is undergoing chemotherapy and using a once-per-cycle neutropenia-prevention option.The short version
- PEGylated filgrastim — the added polymer changes its clearance mechanism so dramatically that dosing shifts from daily to once per chemo cycle.
- A genuinely self-regulating pharmacokinetic design: the drug is cleared mainly by binding neutrophils themselves, so levels stay elevated while neutrophils are low and fall once they recover.
- Approved 2002; multiple biosimilars now compete with the brand.
A self-regulating clearance mechanism
Pegfilgrastim is filgrastim conjugated to a single 20-kDa polyethylene glycol (PEG) molecule at its N-terminus. That added bulk is large enough to essentially eliminate kidney filtration as a clearance route, leaving neutrophil-receptor-mediated uptake as the dominant way the drug leaves the body — a genuinely elegant pharmacokinetic consequence: because clearance depends on binding G-CSF receptors on neutrophils, and neutrophils are exactly what's depleted during the risk window, pegfilgrastim levels stay elevated while the patient is neutropenic and then fall rapidly once neutrophil counts recover and start clearing the drug faster. This self-regulating behavior is what allows a single dose to cover an entire chemotherapy cycle, instead of filgrastim's daily injections.
The approval and pivotal trial
The FDA approved pegfilgrastim (as Neulasta) on 31 January 2002, for the same core indication as filgrastim — reducing infection risk from chemotherapy-induced neutropenia — but dosed once per cycle. A placebo-controlled pivotal trial (Vogel et al., J Clin Oncol 2005, PMID 15718314) in breast cancer patients receiving chemotherapy found pegfilgrastim reduced febrile neutropenia incidence across treatment cycles.
Safety
Shares the same class-wide labeled risks as filgrastim (Warnings and Precautions, not boxed): splenic rupture including rare fatal cases, ARDS, serious allergic/anaphylactic reactions, fatal sickle cell crises in patients with sickle cell disorders, and capillary leak syndrome.
Current status
Still marketed by Amgen as Neulasta, including an on-body injector device for outpatient administration. Multiple FDA-approved biosimilars now compete with the brand, including Fulphila and Udenyca among others.
References
- Vogel CL, Wojtukiewicz MZ, Carroll RR, et al., "First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study," J Clin Oncol 2005;23(6):1178-1184, PMID 15718314.
- FDA approval history for Neulasta (pegfilgrastim), 31 January 2002.